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Background Single-dose nevirapine (NVP) is the main option for the prevention of mother-
to-child transmission (PMTCT) of HIV-1 in countries with limited resources.
However, the use of single-dose NVP results in HIV-1 viral resistance which
could compromise the success of subsequent treatment of mother and child with
antiretroviral combinations that include non-nucleosidic-reverse-transcriptase
inhibitors. This systematic review and meta-analysis of summarized data aimed
to estimate the proportion of mothers and children with NVP resistance
mutations detected in plasma samples 4–8 weeks postpartum after single-dose
NVP use for PMTCT.
Methods Systematic search of electronic databases (MEDLINE, PASCAL) and conference
proceedings (1997 to February 2006). Inclusion of all studies, without design,
place or language restrictions, meeting the following criteria: use of single-dose
NVP; viral genotyping performed with standard sequence analyses, between
4 and 8 weeks postpartum, in plasma samples; available public report; report of
mothers’ median baseline plasma HIV-1 RNA levels. Data extraction by two
independent reviewers using a standardized form created for this purpose.
y The study was presented in part at the Third IAS Conference on HIV
Pathogenesis and Treatment (Rio De Janeiro) 2005: Abstract TuPe5.2P15.
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Logistic random effect models to obtain pooled estimates. Univariable and
multivariable meta-regression to explore sources of heterogeneity.
Results The pooled estimate of NVP resistance prevalence was 35.7% [95% confidence
interval (CI) 23.0–50.6] in women in 10 study arms using single-dose
NVP other antepartum antiretrovirals and 4.5% (CI 2.1–9.4) in three study
arms providing also postpartum antiretrovirals (adjusted odds ratio 0.08; CI
0.04–0.16). The corresponding estimates in children were 52.6% (CI 37.7–67.0)
in seven study arms using single-dose NVP only and 16.5% (CI 8.9–28.3) in eight
study arms combining single-dose NVP with other antiretrovirals.
Conclusions Single-dose NVP is widely used for PMTCT in resource-poor settings, but the
burden of viral resistance is high in both women and children. It is substantially
lower in studies providing additional postpartum antiretrovirals. The clinical
implications of these findings should be further investigated.
Keywords PMTCT, HIV-1, nevirapine resistance, meta-analysis, systematic review
Introduction
In 2006, an estimated 2.3 million children under 15 years were
living with HIV/AIDS worldwide and at least 380 000 died of
AIDS.1 In the same year, almost 530 000 infants became newly
infected with HIV, 90% of them through mother-to-child
transmission (MTCT) before, during or after delivery.1–3
Transmission around the time of delivery accounts for nearly
half of overall MTCT in breastfeeding populations,2,3 and this
peri-partum period has become the major focus of prevention of
MTCT (PMTCT) strategies, especially with antiretroviral drugs
(ARVs). Single-dose nevirapine (NVP) given to the delivering
woman and to the neonate within 72 h of birth has been
proven to be a safe and effective intervention to prevent
MTCT.4,5 The regimen is cheap and relatively easy to admini-
ster. Since 2000, single-dose NVP has been endorsed by the
World Health Organization (WHO) as one of several recom-
mended ARV regimens for PMTCT in resource-limited settings.6
Single-dose NVP induces the selection of HIV-1 resistant
mutants in mothers and infants. However, the extent of this
problem is poorly quantified with estimated prevalence ranging
from 1 to 69% for women and from 0 to 87% for neonates.7–23
Although it has been suggested that NVP-induced resistance
after exposure for PMTCT may impair virological response to
the subsequently used non-nucleosidic-reverse-transcriptase
inhibitors (NNRTIs) in mothers and infants,24,25 this was not
confirmed in recent studies26–28and the clinical implications
remain unclear.20,28,29
Little is known about factors associated with the development
of NVP viral resistance, but it is likely that high HIV-1 RNA levels
in plasma, low CD4 cell counts, viral subtype and NVP plasma
concentration play a role.7,30 Recent preliminary results from a
randomized trial in South Africa (Treatment Options
Preservations Study or TOPS) suggest that the use of a short
(4 or 7 days) post-partum regimen of zidovudine (ZDV)þ
lamivudine (3TC) given to the mother after single-dose NVP
intake substantially reduces the rate of NVP resistance,21 and
this was confirmed in an observational study in Coˆte d’Ivoire.8
We performed a systematic review and a meta-analysis of
available data to estimate the prevalence of NVP viral resistance
mutations in mothers and HIV-1-infected children and explore
sources of between-study heterogeneity, including additional
ARV interventions given post-partum.
Methods
Search strategy
MEDLINE and PASCAL were searched for published articles
between 1997 and February 2006 using a combination of the
terms ‘Resistance AND [(nevirapine OR NVP) OR NNRTI]’.
Searches were complemented by perusing references of
retrieved articles. Studies presented at conferences
(US Conference on Retroviruses and Opportunistic Infections,
International AIDS Conference, International HIV Drug
Resistance Workshop, Conference on HIV Pathogenesis and
Treatment; 2000–06) were also searched using NLM Gateway,
conference websites or conference proceedings.
Inclusion criteria
All studies, without design, place or language restrictions,
were considered if they met the following four selection criteria:
(i) a single-dose NVP had been given to HIV-1 infected women
during labour, (ii) viral genotypic resistance assay had been
performed with sequence analyses (detection limit 20–30%),
between 4 and 8 weeks post-partum, in mothers and children’s
plasma samples, (iii) an abstract, an article or an oral or poster
presentation was available and (iv) for the meta-analysis on
mothers’ findings only, median baseline plasma HIV-1 RNA
level was reported.
When a study had two or more intervention arms, only those
where women had received single-dose NVP were included in
the meta-analysis. When multiple communications were avail-
able for the same study, we included the most recent one and/
or the one with the largest number of observations. The
homogeneity relative to the genotypic assessment methods used
in the included studies was checked by the virologists. Studies
using sensitive drug resistance assays (detection limit <1%) in
plasma sample were retained for a complementary analysis to
estimate the proportion of patients with NVP viral resistance
mutations using these methods.
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Data extraction
Two independent observers (EA, DKE) independently assessed
the eligibility of studies using a standardized form developed
for this purpose. Disagreements between reviewers were
resolved through discussion. Data extraction was done by the
same reviewers using a standardized data extraction form
created for this study and with help from others when needed
(RT, BM, PVDP, CR). The following information was obtained
from each study: first author’s name, journal and year of
publication/presentation and details on the principal study in
case the resistance study was a substudy; patient inclusion and
exclusion criteria in the primary study and in the resistance
study; place of study; ARV intervention(s); methods used for
resistance testing; median baseline plasma HIV-1 RNA viral
load; and for all assessments, when available, timing, number
of available samples, number of successful analyses, number of
study participants with NVP resistance mutations. We asked
authors of primary studies to check the accuracy of extracted
data and supply additional data if required.
Outcome measures
The outcomes of interest were the proportions of mothers
and children with NVP resistance viral mutations in codons
of the viral reverse transcriptase gene known to confer
resistance to NVP (100, 103, 106, 108, 181, 188, 190)31
detected in plasma samples collected between 4 and 8 weeks
post-partum.
Data synthesis and exploration of heterogeneity
The proportion of study participants with NVP resistance
mutations from each selected study was graphically displayed
with the 95% confidence interval (CI) in a forest plot. The
overall prevalence of NVP resistance mutations and its 95% CI
was estimated with a random effect logistic model (PROC
NLMIXED in SAS software version 8.2 USA).32,33 The number
of degrees of freedom was calculated as the number of study
arms minus the number of parameters estimated in the model.
Between-study heterogeneity was assessed using the like-
lihood ratio test of the random effect component which had a
50 : 50 mixture distributions of X2qþ1 and X
2
q, asymptotically
(where q was the number of parameter estimates under the
null hypothesis). Univariable and multivariable meta-
regressions were conducted to quantify potential sources of
heterogeneity34,35 such as study and report characteristics.
Study characteristics included:
(i) Administration of ante/intrapartum ARV regimen in
addition to single-dose NVP
(ii) Administration of post-partum ARV regimen in addition
to single-dose NVP
(iii) Study location: in Southern Africa vs other regions
(iv) Median baseline plasma HIV-1 RNA viral load, dichot-
omized at the median value
(v) Time of resistance assessment: at 4 weeks vs 6–8 weeks
post-partum
(vi) Sample size, dichotomized at 30 study participants
(vii) Reported pre-NVP exposure resistance assessment
(viii) Exhaustivity of the sample with resistance assessment
compared with the sample enrolled in the main study.
Report characteristics included:
(i) Publication type
(ii) Status of the reported results: final or preliminary.
Variables with P-value <0.20 in univariable models were
examined in multivariable models using a forward stepwise
procedure. When between-study variance failed to be calcu-
lated, no further independent variable was added in the
random effect models and fixed effects models were used.
All P-values were two-tailed.
Results
Prevalence of resistance in mothers
Among 74 reports identified from 20 investigators, 64 were
excluded because they were either duplicates or met exclusion
criteria (Figure 1). The investigators were contacted and
eight responded. Seven reports could thus be updated, one
still failing to meet every inclusion criterion. Answers from the
other investigators would have allowed the re-evaluation for
eligibility of four additional studies.
Ten reports were thus included in the final analysis, relating
to nine studies reported between 2000 and 2006 and
corresponding to 13 study arms and 1173 women overall. The
arms of the studies included in the meta-analysis were
described in Table 1.
Of the nine included studies, one (the TOPS trial)21 had
three post-partum intervention arms, two [the ANRS (Agence
Nationale de Recherche sur le Sida et les he´patites virales)]
1201 DITRAME (DIminution de la TRAnsmission Me`re-Enfant)
Plus cohort7,8 and the South African PMTCT cohort)20 had
two intervention arms (Table 1). Four studies took place in
Southern Africa (South Africa, Zimbabwe and Malawi), and
two in Eastern Africa (Uganda). Published articles were
available for six studies, as well as an unpublished report
for one of them, poster/slides for two studies and an
abstract for one. Results were reported as final for six studies.
Genotypic resistance assessment prior to single-dose NVP use
in women with NVP resistance at 4–8 weeks post-partum
or in a subset had been described for six studies. The
median of the reported median baseline plasma HIV-1
RNA viral loads was 4.39 log10 copies/ml [interquartile range
(IQR): 4.00–4.48].
In univariable meta-regression (Table 2), both the use of
ante- and post-partum ARV regimens were associated with a
lower NVP resistance prevalence, as was a higher median
baseline plasma HIV-1 RNA viral load. The univariable inverse
relation between baseline HIV-1 RNA viral load and
occurrence of NVP resistance did not hold when this
variable was adjusted for post-partum ARV intervention.
Development of NVP resistance mutations was more frequent
in studies in Southern Africa. In multivariable meta-
regression (Table 2), no more than two independent variables
could be added in the random effect model. Post-partum
ARV regimen, study location and baseline median viral
load remained strongly associated with the detection of NVP
resistance mutations.
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Using univariable random effect models with the post-partum
ARV regimen variable (Figure 2), the pooled estimate of NVP
resistance prevalence in the 10 study arms using single-dose
NVP other ante/intra-partum ARVs was 35.7% (n¼ 950, CI:
23.0–50.6), and 4.5% (n¼ 223, CI: 2.1–9.4) in three study arms
providing also post-partum ARVs.
Complementary analysis from results using
sensitive drug resistance assays in mothers
Five studies using sensitive drug resistance assays were
identified (Table 3). We excluded from the analysis the
women who received other ARV in addition to single-dose
NVP (arms 2 and 3 of the TOPS trial). Using a random
effect model with no explanatory variable, the pooled
estimate of NVP resistance prevalence was 62.4% (n¼ 423;
CI: 41.7–79.5).
Prevalence of resistance in offspring
Among 35 relevant reports, 24 were excluded because they were
either duplicates or met exclusion criteria (Figure 3), giving 11
reports for inclusion in the final analysis, relating to 10 studies
reported between 2000 and 2006, corresponding to 15 study
arms and 339 children overall. Five of these studies were also
included in the meta-analysis of NVP resistance in mothers.
The arms of the studies included in the meta-analysis were
described in Table 4.
Of the 15 study arms, four included both a maternal ante/
intrapartum ARV intervention and an infant ARV prophylaxis
with ZDV added to single-dose NVP.7,8,13,22 In one study arm,
a second post-partum dose of NVP was provided23 and in two
other arms, both maternal postpartum and neonatal ZDVþ 3TC
interventions were given21 (TOPS arms 2 and 3). Another arm
provided ante/intrapartum and postpartum ZDVþ 3TC plus
infant ZDV prophylaxis8 and another one, infant ZDV prophy-
laxis only.13 Six studies took place in Southern Africa (South
Africa and Malawi). All studies performed the genotypic
assessment at 6–8 weeks post-natal. Median sample size was
23 (IQR: 10–29). An article was available for three studies, as
well as an unpublished report for one of them, conference
presentations (slides or posters) for four studies and abstracts
for three.
In univariable meta-regression (Table 5), antepartum, post-
partum and post-natal ZDV or ZDVþ 3TC interventions were
associated with lower NVP resistance prevalence in children.
Location in Southern Africa was associated with higher NVP
resistance. In multivariable analysis (Table 5), antepartum and
post-partum ARV interventions remained strongly associated
with lower NVP resistance prevalence in children, but not
neonatal ARVs and geographical location.
Using a univariable random effect model, the pooled
estimates of NVP resistance prevalence were 52.6% (n¼ 201;
CI 37.7–67.0) in the group of seven study arms using NVP only
and 16.5% (n¼ 138; CI 8.9–28.3) in the group of eight study
arms combining NVP with ZDV or ZDVþ 3TC interventions
(Figure 4).
Discussion
We estimated that about one-third of women and more
than half of children who became HIV-1-infected despite
PMTCT, developed NVP resistance mutations after single-dose
NVP intake, but this rate was reduced to about 4% and 16%,
respectively, if additional short-course ARV regimens were
given, post-partum ZDV and 3TC in particular. These
pooled estimates should be interpreted with caution as the
heterogeneity among the intervention groups remained
important due to other factors assessed in the multivariable
analyses.
A strength of our study is our effort to assess potential
sources of between-study heterogeneity. Although we included
only reported studies, our systematic review had a comprehen-
sive coverage, thus limiting publication bias. Indeed, we believe
that all NVP resistance studies which have been completed or
are in progress, have been reported, whatever their results, at
least as a conference communication.
The outcome of interest was standardized between studies,
and we restricted our analysis to results of plasma samples
acknowledging that NVP resistance mutations may differ
between compartments (peripheral blood mononuclear cells or
breast milk).7,17
The genotypic resistance assessment methods, all sequence
analyses, were reasonably equivalent between studies
included in the meta-analyses. We did not include
studies using the more sensitive recent techniques36–40 in the
main analysis, partly because the clinical implications of
Potentially relevant reports identified by literature search (n>1244)
-   Pubmed/Pascal (1997–Feb 2006)*, n=549
-   Gateway (2000–2006)*, n= 629
-   International HIV Drug Resistance Workshops (2000–2006), n=NA
-   12th CROI (2005)**, n=24
-   3rd IAS Conference (2005)**, n=29




Reports included in the
meta-analysis (n=10)
Reports excluded because
-   duplicates (n=27)
-   meeting exclusion 
criteria$ (n=37)
Figure 1 Flow chart of studies included in the meta-analysis on
prevalence of viral resistance to nevirapine in mothers after single-dose
exposure to prevent vertical transmission of HIV-1. Terms of search:
‘‘Resistance AND ((nevirapine OR NVP) OR NNRTI)’’. NNRTI¼non
nucleosidic reverse transcriptase inhibitors. Terms of search: ‘‘nevir-
apine’’ and ‘‘NVP’’. CROI¼Conferences on Retroviruses and
Opportunistic Infection. IAS¼ International AIDS Society. NA¼not
available. $See definition in the text
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Table 1 Characteristics of resistance studies included in the meta-analysis on prevalence of resistance to nevirapine in mothers after single-dose nevirapine to prevent vertical transmission of HIV-1
Study
Arms with intervention





































































Article Malawi NVAZ RCT Intrapartum
sdNVP




In a subset of
women
6–8 weeks 4.78 65 69.2
Lee et al.17 Article Zimbabwe HPTN 023 RCT Intrapartum sdNVP NI Final results NI TruGen HIV-1
kit (Visible
Genetics)
















































Article Uganda HIVNET 012 RCT Intrapartum
sdNVP








6 weeks 4.4 279 25.1
Jackson
et al.16
Article Uganda HIVNET 006 OS Intrapartum
sdNVP


















































6 weeks 3.48(2) 95 14.7
RCT: randomised controlled trial; OS: Observational study; NI: no information; NVPR: NVP resistance; ZDV: Zidovudine; sdNVP: single-dose Nevirapine; 3TC: Lamivudine; CBV: Combivir (ZDVþ 3TC); For study arms
with antepartum ARV intervention: (1)plasma viral load performed at inclusion (2)plasma viral load performed at delivery; PMTCT: Prevention of Mother-To-Child-Transmission; TOPS: Treatment Options Preservations
Study; NVAZ:Nevirapine-AZT (zidovudine); HPTN: HIV Prevention Trials Network; ANRS: Agence Nationale de Recherches sur le Sida et les he´patites virales; DITRAME: DIminution de la TRAnsmission Mere-Enfant;
HIVNET: HIV Network for Prevention Trial; CDC: Center for Diseases Control; PACTG: Pediatric AIDS Clinical Truials Group Protocol.



































Table 2 Univariable and mutivariable meta-regression on prevalence of nevirapine (NVP) viral resistance in women at 4–8 weeks postpartum after single-dose exposure to prevent vertical
transmission of HIV-1
Variables Univariable Multivariable Multivariable
Random effect models Random effect models Fixed effect model
OR [CI]a P-value OR [CI]a P-value OR [CI]a P-value OR [CI]a P-value OR [CI]a P-value
Postpartum ARV intervention
Yes vs No (Ref.)
0.07 [0.03–0.15] <104 – – 0.08 [0.04–0.16] <104 0.04 [0.01–0.14] <103 0.07 [0.03–0.13] <104
Ante/Intrapartum ARV intervention
Yes vs No (Ref.)
0.29 [0.12–0.75] 0.016 0.6 [0.20–1.72] 0.3 – – – – – –
Study location Southern Africa vs
other regions (Ref.)
3.81 [1.73–8.40] 0.004 2.7 [0.97–7.46] 0.06 4.69 [2.58–8.51] <103 – – 5.05 [3.57–7.14] <104
Median baseline median plasma
viral load44.39 log10 copies/ml
vs 44.39 (Ref.)
0.11 [0.05–0.23] <104 – – – – 1.93 [0.61–6.16] 0.23 1.53 [1.08–2.17] 0.022
Time of resistance assessment
4 weeks vs 6–8 weeks postpartum (Ref.)
0.37 [0.10–1.32] 0.111 – – – – – – – –
Exhaustivityb Yes vs No (Ref) 1.81 [0.54–6.00] 0.298 – – – – – – – –
Status of the results Preliminary or no
information vs final (Ref.)
1.09 [0.44–2.69] 0.838 – – – – – – – –
Sample size <30 vs 530 (Ref.) 0.56 [0.05–6.14] 0.599 – – – – – – – –
Pre-NVP exposure resistance assessment
Yes vs no information (Ref.)
0.74 [0.16–3.35] 0.669 – – – – – – – –
Publication type Articles vs
other types (Ref.)
0.10 [0.02–0.41] 0.004 – – – – – – – –
Between-study variance – – – <103 – 0.314 – <104 – –
aOdds Ratio [Limits of 95% confidence interval]. ARV: antiretroviral.


































their results were unclear and partly because we did not
want to introduce further heterogeneity and data overlap.
However, complementary analysis of only studies using
these more sensitive NVP-resistance assays showed a
prevalence of resistance of 62%, and our results should thus
be considered a minimum estimate of prevalence of NVP
resistance. Finally, it has been previously reported that
NVP resistance mutations could fade over time.14 The NVP
resistance rates reported in this meta-analysis were all observed
within a homogeneous short post-partum treatment period
that ranged between 4 and 8 weeks. This increases the validity
of our pooled estimates.
Our study has several limitations. First, reporting bias could
have affected our findings. Because of lack of information,
we were unable to adjust for treatment characteristics such as
the percentage of women who received a second dose of NVP,
after false or prolonged labour, or HIV-1 subtypes which
have previously been identified to be associated with NVP
resistance.13 However, we could adjust for study location,
thus taking indirectly into account HIV-1 subtypes which are
geographically distributed. In the meta-analysis in children, we
could not evaluate the effect of duration of post-natal
prophylaxis or that of regimen (ZDV only vs ZDVþ 3TC) due
to the very limited number of reported studies. Some data were
only available from abstracts or internal reports, although these
were not yet peer-reviewed. However, most of them had already
been presented at several occasions in international confer-
ences, which provides some guarantee of quality. Secondly,
although the indirect comparisons we have conducted could be
subject to greater bias than a randomized design (especially
selection bias), in the absence of such ‘ideal’ studies, the model
we used was appropriately adapted to the complex nature of
the data.41
Exposure to antepartum ARVs was not associated with
resistance risk in mothers in multivariable analysis. However,
this may be due to the fact that it was administrated in one of
the two studies providing also post-partum ARVs. Similarly,
ZDV syrup was routinely given to neonates in studies where
mothers were offered antenatal ARV intervention, before single-
dose NVP and it was not possible to distinguish the effect of
maternal and neonatal ZDV on the risk of NVP resistance in
infants. Considering the different resistance profiles described
Figure 2 Forest plot of prevalence of viral resistance to nevirapine (NVP) in mothers at 4–8 weeks postpartum after single-dose exposure, grouped
according to whether mothers received or not additional postpartum antiretroviral (ARV) therapy (univariable random effect model). yZidovudine or
ARV combination. zZidovudine and lamivudine. TOPS: Treatment Options Preservations Study. NVAZ:Nevirapine-AZT (zidovudine). HPTN: HIV
Prevention Trials Network. DITRAME: DIminution de la TRAnsmission Mere-Enfant. HIVNET: HIV Network for Prevention Trial. PACTG: Pediatric
AIDS Clinical Trials Group Protocol
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in mothers (K103N) and children (Y181C) in most studies
included in this meta-analysis,8,14,15,18,19,23 the acquisition of
resistant virus may be more likely to be due to a sub-optimal
neonatal prophylaxis than to the transmission of such virus by
the mother. In one study, the K103N was the most common
mutation observed in children22 and the authors suggested this
could be in relation with the pressure of ZDV prophylaxis on
the CRF01_AE subtype.
In the meta-analysis on NVP resistance in mothers, study
location in Southern Africa was independently associated with
a higher NVP resistance prevalence, which could be due, in
part, to the high prevalence of viral subtype C.12,42 In Coˆte
d’Ivoire, where the prevalence of NVP resistance prevalence
was lowest and where women received additional antepartum
and post-partum ARVs, the main subtype is CRF02-AG.
However, other reports have shown resistance frequencies
similar to those observed in other countries where other
variants predominate: 33.3% in a group of women receiving
additional ante/intra-partum ARVs7 and 20.7% in a group of
women receiving single-dose NVP only43 (publication not
included in our analysis due to the lack of availability
of baseline plasma RNA viral load).
Allowing for study location and post-partum intervention,
we also confirmed that the prevalence of NVP resistance
increased with higher baseline HIV-1 RNA viral load.6
Although this finding should be interpreted with caution due
to the risk of aggregation bias,35 this result raises a potential










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Potentially relevant reports identified by literature search (n>1244)
-   Pubmed/Pascal (1997–Feb 2006)*, n=549
-   Gateway (2000–2006)*, n= 629
-   International HIV Drug Resistance Workshops (2000–2006), n=NA
-   12th CROI (2005)**, n=24
-   3rd IAS Conference (2005)**, n=29 




Reports included in the
meta-analysis (n=11)
Reports excluded because
-   duplicates (n=17)
-   meeting exclusion
criteria$ (n=7)
Figure 3 Flow chart of studies included in the meta-analysis on
prevalence of viral resistance to nevirapine in children after single-dose
exposure to prevent vertical transmission of HIV-1. Terms of search:
‘‘Resistance AND ((nevirapine OR NVP) OR NNRTI)’’. NNRTI¼non
nucleosidic reverse transcriptase inhibitors. Terms of search:
‘‘nevirapine’’ and ‘‘NVP’’. CROI¼Conferences on Retroviruses and
Opportunistic Infection. IAS¼ International AIDS Society. NA¼not
available. $See definition in the text
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Table 4 Characteristics of resistance studies included in the meta-analysis on prevalence of resistance to nevirapine in children after single-dose nevirapine to prevent vertical transmission of HIV-1
Arms with intervention of interest Reported Method of Time of genotypic %





























SAINT RCT Intrapartum sdNVPþ
Postpartum sdNVP
sdNVP NI NI NI 4-6 weeks 40 52.5
Eshleman
et al.13
Article Malawi NVAZ RCT Intrapartum sdNVP Arm 1: sdNVP
Arm 2: sdNVPþ
7 days ZDV
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DNA sequencing
































OS 1.0: Antenatal ZDVþ
intrapartum ZDVþ sdNVP
1.1: Antenatal ZDVþ 3TCþ
intrapartum ZDVþ 3TCþ
sdNVPþ postpartum
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RCT: randomised controlled trial; OS: Observational study; NI: no information; NVPR: NVP resistanc; ZDV: Zidovudine; sdNVP: single-dose Nevirapine; 3TC: Lamivudine; CBV: Combivir (ZDVþ 3TC); TOPS:
Treatment Options Preservations Study; SAINT: South African Intrapartum Nevirapine Trial; NVAZ:Nevirapine-AZT (zidovudine); PMTCT: Prevention of Mother-To-Child-Transmission; KZN: KwaZulu-Natal;
ANRS: Agence Nationale de Recherches sur le Sida et les he´patites virales; DITRAME: DIminution de la TRAnsmission Mere-Enfant; HIVNET: HIV Network for Prevention Trial; CDC: Center for Diseases Control;
PHPT: Perinatal HIV Prevention Trial.



































eligible for treatment sooner after the delivery than women
with lower baseline HIV-1 RNA viral load. This was highlighted
by Lockman et al.25 who demonstrated that virological
suppression was less frequent in women who initiated NVP-
based ART <6 months from single-dose NVP exposure and
among infants while this association was not found among
women initiating the same kind of treatment 6 months or more
from sdNVP exposure. Results from recent studies did not
suggest a difference in terms of clinical or immunological
response to NVP-containing ARV treatments28,29 or efficacy of
NVP-containing regimens for PMTCT in subsequent pregnan-
cies20,44 in women previously exposed to single-dose NVP.
However, it cannot be excluded that NVP-resistant viruses
following single-dose NVP exposure, even below the threshold
of detection of conventional assays or archived in biological
reservoirs may impair response to subsequent NNRTI-contain-
ing regimens.24,25
In conclusion, we confirm a substantial reduction in the
prevalence of NVP resistance after single-dose NVP to prevent
MTCT with the addition of a short course of dual ARV regimen
(ZDVþ 3TC) given to the mother post-partum. Given the high
likelihood of viral resistance associated with single-dose NVP
use alone, here estimated at 35.7% in mothers and 52.6% in
children and the uncertain clinical implications in settings
where NVP is included in first-line ARV treatment regimen, we
suggest that a short-course post-partum ARV regimen should
be routinely recommended.6 This is of particular importance in
settings where sub-type C is predominant. For women with
high baseline HIV-1 RNA viral load and more advanced disease,
fully suppressive ARV therapy, instead of single-dose NVP
containing PMTCT regimens, is already recommended, partly to
reduce the risk of resistance to NVP.6 Further studies are
needed to assess the association between single-dose NVP
exposure, not only in the proportion of resistant mutants in
plasma but also in the different compartments and subsequent
response to NNRTI-based treatment in mothers and children.
Furthermore, alternative regimens to prevent MTCT need
urgent evaluation.
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